Financial reports
10-K
2023 FY
Annual report
5 Mar 24
10-Q
2023 Q3
Quarterly report
9 Nov 23
10-Q
2023 Q2
Quarterly report
11 Aug 23
10-Q
2023 Q1
Quarterly report
12 May 23
ARS
2022 FY
Annual report to shareholders
21 Apr 23
10-K
2022 FY
Annual report
8 Mar 23
10-Q
2022 Q3
Quarterly report
10 Nov 22
10-Q
2022 Q2
Quarterly report
12 Aug 22
10-Q
2022 Q1
Quarterly report
12 May 22
10-K
2021 FY
Annual report
18 Mar 22
Current reports
8-K
Jasper Therapeutics Reports Fiscal 2023 Financial Results and Recent Corporate Developments
4 Mar 24
8-K
Jasper Therapeutics Announces Pricing of $50 Million Underwritten Offering of Common Stock
6 Feb 24
8-K
Material Modifications to Rights of Security Holders
4 Jan 24
8-K
Jasper Therapeutics, Inc. Announces Reverse Stock Split
2 Jan 24
8-K
Submission of Matters to a Vote of Security Holders
20 Dec 23
8-K
Jasper Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update
9 Nov 23
8-K
Jasper Therapeutics Announces Appointment of Thomas G. Wiggans as Chairperson of the Board of Directors
1 Nov 23
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
20 Oct 23
8-K
Regulation FD Disclosure
10 Oct 23
8-K
Jasper Therapeutics Announces IND Clearance for Phase 1b/2a Study of Subcutaneous Briquilimab in Chronic Spontaneous Urticaria
10 Oct 23
Registration and prospectus
S-8
Registration of securities for employees
5 Mar 24
424B5
Prospectus supplement for primary offering
7 Feb 24
S-8
Registration of securities for employees
11 Aug 23
424B5
Prospectus supplement for primary offering
5 May 23
S-3
Shelf registration
28 Apr 23
S-8
Registration of securities for employees
8 Mar 23
424B5
Prospectus supplement for primary offering
25 Jan 23
424B5
Prospectus supplement for primary offering
24 Jan 23
424B5
Prospectus supplement for primary offering
10 Nov 22
424B3
Prospectus supplement
17 Oct 22
Proxies
DEF 14A
Definitive proxy
20 Nov 23
PRE 14A
Preliminary proxy
9 Nov 23
DEFA14A
Additional proxy soliciting materials
21 Apr 23
DEF 14A
Definitive proxy
21 Apr 23
PRE 14A
Preliminary proxy
10 Apr 23
DEFA14A
Additional proxy soliciting materials
29 Apr 22
DEF 14A
Definitive proxy
29 Apr 22
DEF 14A
Definitive proxy
4 Dec 20
Other
EFFECT
Notice of effectiveness
8 May 23
CORRESP
Correspondence with SEC
3 May 23
UPLOAD
Letter from SEC
2 May 23
EFFECT
Notice of effectiveness
19 Oct 22
EFFECT
Notice of effectiveness
14 Oct 22
CORRESP
Correspondence with SEC
14 Oct 22
UPLOAD
Letter from SEC
13 Oct 22
EFFECT
Notice of effectiveness
30 Mar 22
EFFECT
Notice of effectiveness
27 Oct 21
CORRESP
Correspondence with SEC
22 Oct 21
Ownership
SC 13G
Avidity Partners Management LP
27 Mar 24
4
Jeetinder Singh Mahal
12 Mar 24
144
Notice of proposed sale of securities
12 Mar 24
144
Notice of proposed sale of securities
6 Mar 24
4
RON MARTELL
20 Feb 24
4
Jeetinder Singh Mahal
20 Feb 24
4
HERB CROSS
20 Feb 24
4
Edwin Jonathan Tucker
20 Feb 24
SC 13G/A
CITADEL ADVISORS LLC
14 Feb 24
SC 13G/A
Qiming U.S. Healthcare Fund II, L.P.
14 Feb 24